nAMD: Switching Therapies - what you need to know

Program Goal

Currently Available Anti-VEGF Therapies Used to Treat nAMD

12-Month Outcomes of Ranibizumab vs Aflibercept: Similar Rates of VA Improvement

Factors That Determine The Reason to Switch Therapies

EMR Study: Real World Ranibizumab Data Vs Benchmark Standards of Care

Real-World Visual Outcomes at Centers Across UK Differ From Randomized Trials

Is It Beneficial for a Patient to Switch?

Results May Vary After Switching Therapies

Two Main Reasons for Switching Therapies

Visual Function of Patient is Most Important

Can Anatomical Endpoints Guide Decisions to Switch Therapies?

Benefit of Switching: Theory

Switching From Ranibizumab to Aflibercept: Real-Life Data

Switching From Ranibizumab to Aflibercept: Real-Life Data (cont)

Significance of Switching: Study Results

The Mechanisms of Tachyphylaxis

Meta-Analysis of Studies of Patients With Treatment Resistant nAMD: Methods

Meta-Analysis Indicates High Number of Injections May Cause Resistance

Concepts of Tachyphylaxis: More Data is Needed

Concepts of Tachyphylaxis: Change in Underlying Disease

Factors That Involve Decisions to Switch Therapies

CATT Study: Results Show Discontinuous Therapy Inferior to Continuous Therapy

Real-Life Data Studies May Differ From Clinical Trial Data

Response to Anti-VEGF Therapy in nAMD

Is a Loading Phase Needed After Switching?

Patient Case Scenario

Switching Study: Ranibizumab to Aflibercept to Ranibizumab

Concluding Remarks

Abbreviations

Abbreviations (cont)